A citation-based method for searching scientific literature

Meichen Gu, Tiankai Xu, Pengyu Chang. Ther Adv Med Oncol 2021
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype.
Nicole M Sodir, Roderik M Kortlever, Valentin J A Barthet, Tania Campos, Luca Pellegrinet, Steven Kupczak, Panayiotis Anastasiou, Lamorna Brown Swigart, Laura Soucek, Mark J Arends,[...]. Cancer Discov 2020
44
66

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
367
66

Robust enumeration of cell subsets from tissue expression profiles.
Aaron M Newman, Chih Long Liu, Michael R Green, Andrew J Gentles, Weiguo Feng, Yue Xu, Chuong D Hoang, Maximilian Diehn, Ash A Alizadeh. Nat Methods 2015
66

YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Ralph Gruber, Richard Panayiotou, Emma Nye, Bradley Spencer-Dene, Gordon Stamp, Axel Behrens. Gastroenterology 2016
108
33

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
J Smeby, A Sveen, M A Merok, S A Danielsen, I A Eilertsen, M G Guren, R Dienstmann, A Nesbakken, R A Lothe. Ann Oncol 2018
43
33

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Friederike Inga Nollmann, Dietrich Alexander Ruess. Biomedicines 2020
7
33

Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion.
Li-Lian Gan, Ling-Wei Hii, Shew-Fung Wong, Chee-Onn Leong, Chun-Wai Mai. Cancers (Basel) 2020
6
33

Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
Timothy J Humpton, Brinda Alagesan, Gina M DeNicola, Dan Lu, Georgi N Yordanov, Carl S Leonhardt, Melissa A Yao, Priya Alagesan, Maya N Zaatari, Youngkyu Park,[...]. Cancer Discov 2019
44
33

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Xiao Zhao, Xiuchao Wang, Lijun Fang, Chungen Lan, Xiaowei Zheng, Yongwei Wang, Yinlong Zhang, Xuexiang Han, Shaoli Liu, Keman Cheng,[...]. Cancer Lett 2017
33
33

Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Changqing Xie, Austin G Duffy, Gagandeep Brar, Suzanne Fioravanti, Donna Mabry-Hrones, Melissa Walker, Cecilia Monge Bonilla, Bradford J Wood, Deborah E Citrin, Elizabeth M Gil Ramirez,[...]. Clin Cancer Res 2020
17
33

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.
Max D Wellenstein, Karin E de Visser. Immunity 2018
234
33

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
519
33

The consensus molecular subtypes of colorectal cancer.
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino,[...]. Nat Med 2015
33

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Gregory L Beatty, Rafael Winograd, Rebecca A Evans, Kristen B Long, Santiago L Luque, Jae W Lee, Cynthia Clendenin, Whitney L Gladney, Dawson M Knoblock, Patrick D Guirnalda,[...]. Gastroenterology 2015
153
33

Immunogenicity of somatic mutations in human gastrointestinal cancers.
Eric Tran, Mojgan Ahmadzadeh, Yong-Chen Lu, Alena Gros, Simon Turcotte, Paul F Robbins, Jared J Gartner, Zhili Zheng, Yong F Li, Satyajit Ray,[...]. Science 2015
411
33

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Andrew M Waters, Channing J Der. Cold Spring Harb Perspect Med 2018
238
33

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Xiaomeng Liu, Jin Xu, Bo Zhang, Jiang Liu, Chen Liang, Qingcai Meng, Jie Hua, Xianjun Yu, Si Shi. Mol Cancer 2019
21
33

Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.
Dominic E Sanford, Brian A Belt, Roheena Z Panni, Allese Mayer, Anjali D Deshpande, Danielle Carpenter, Jonathan B Mitchem, Stacey M Plambeck-Suess, Lori A Worley, Brian D Goetz,[...]. Clin Cancer Res 2013
309
33

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
537
33




Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
33

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
M Aglietta, C Barone, M B Sawyer, M J Moore, W H Miller, C Bagalà, F Colombi, C Cagnazzo, L Gioeni, E Wang,[...]. Ann Oncol 2014
104
33

Cancer stem cells: implications for cancer therapy.
Shaheenah Dawood, Laura Austin, Massimo Cristofanilli. Oncology (Williston Park) 2014
195
33

Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
Efsevia Vakiani, Manickam Janakiraman, Ronglai Shen, Rileen Sinha, Zhaoshi Zeng, Jinru Shia, Andrea Cercek, Nancy Kemeny, Michael D'Angelica, Agnes Viale,[...]. J Clin Oncol 2012
210
33

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
Emma M Kerr, Edoardo Gaude, Frances K Turrell, Christian Frezza, Carla P Martins. Nature 2016
181
33

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill,[...]. J Clin Oncol 2018
751
33

T cell exclusion, immune privilege, and the tumor microenvironment.
Johanna A Joyce, Douglas T Fearon. Science 2015
945
33

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
316
33

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
Sunil R Hingorani, Lifu Wang, Asha S Multani, Chelsea Combs, Therese B Deramaudt, Ralph H Hruban, Anil K Rustgi, Sandy Chang, David A Tuveson. Cancer Cell 2005
33

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Adam L Burrack, Ellen J Spartz, Jackson F Raynor, Iris Wang, Margaret Olson, Ingunn M Stromnes. Cell Rep 2019
37
33

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Elizabeth Allen, Arnaud Jabouille, Lee B Rivera, Inge Lodewijckx, Rindert Missiaen, Veronica Steri, Kevin Feyen, Jaime Tawney, Douglas Hanahan, Iacovos P Michael,[...]. Sci Transl Med 2017
296
33

Development of PARP and Immune-Checkpoint Inhibitor Combinations.
Ross A Stewart, Patrick G Pilié, Timothy A Yap. Cancer Res 2018
86
33



Pancreatic cancer.
Terumi Kamisawa, Laura D Wood, Takao Itoi, Kyoichi Takaori. Lancet 2016
33

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto,[...]. J Clin Oncol 2020
133
33

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Chunwan Lu, Amy V Paschall, Huidong Shi, Natasha Savage, Jennifer L Waller, Maria E Sabbatini, Nicholas H Oberlies, Cedric Pearce, Kebin Liu. J Natl Cancer Inst 2017
102
33

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
Claudio Luchini, Lodewijk A A Brosens, Laura D Wood, Deyali Chatterjee, Jae Il Shin, Concetta Sciammarella, Giulia Fiadone, Giuseppe Malleo, Roberto Salvia, Valentyna Kryklyva,[...]. Gut 2021
39
33

Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
S Murakami, D Shahbazian, R Surana, W Zhang, H Chen, G T Graham, S M White, L M Weiner, C Yi. Oncogene 2017
95
33

Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
Weiying Zhang, Nivedita Nandakumar, Yuhao Shi, Mark Manzano, Alias Smith, Garrett Graham, Swati Gupta, Eveline E Vietsch, Sean Z Laughlin, Mandheer Wadhwa,[...]. Sci Signal 2014
223
33

Drugging the undruggable RAS: Mission possible?
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
929
33

TGF-β function in immune suppression.
Akihiko Yoshimura, Go Muto. Curr Top Microbiol Immunol 2011
127
33

KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
Neeraj Lal, Brian S White, Ghaleb Goussous, Oliver Pickles, Mike J Mason, Andrew D Beggs, Philippe Taniere, Benjamin E Willcox, Justin Guinney, Gary W Middleton. Clin Cancer Res 2018
57
33

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh,[...]. N Engl J Med 2013
33

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
290
33

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, Dan G Duda, Rakesh K Jain. Nat Rev Clin Oncol 2018
504
33

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.
Gina M DeNicola, Florian A Karreth, Timothy J Humpton, Aarthi Gopinathan, Cong Wei, Kristopher Frese, Dipti Mangal, Kenneth H Yu, Charles J Yeo, Eric S Calhoun,[...]. Nature 2011
33

Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Nithya Sivaram, Patrick A McLaughlin, Han V Han, Oleksi Petrenko, Ya-Ping Jiang, Lisa M Ballou, Kien Pham, Chen Liu, Adrianus Wm van der Velden, Richard Z Lin. J Clin Invest 2019
20
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.